3 Diabetes Biotechs That Could Surge 50% or More in 2018 Post author:Sam Post published:January 21, 2018 Post category:BioPharma Wall Street projects these three biotechs will grow the fastest over the next 12 months. Source: BioSpace You Might Also Like Alimera Sciences To Report Second Quarter 2017 Financial Results On August 2nd, 2017 July 23, 2017 IMRALDI, Biogen???s Adalimumab Biosimilar Referencing Humira, Is Approved In The European Union August 24, 2017 Biogen Release: Company Reports 2016 Revenues Of $11.4 Billion January 25, 2017
IMRALDI, Biogen???s Adalimumab Biosimilar Referencing Humira, Is Approved In The European Union August 24, 2017
